Immunome (IMNM.US) was first covered by Piper Sandler, which gave it an increase rating, and the target price was $27.00.
Immunome Analyst Ratings
Piper Sandler Initiates Coverage On Immunome With Overweight Rating, Announces Price Target of $27
Immunome's Promising Pipeline and Strategic Positioning Affirm Buy Rating
TD Cowen Sticks to Their Buy Rating for Immunome (IMNM)
Immunome Analyst Ratings
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
Immunome Analyst Ratings
Guggenheim Initiates Coverage On Immunome With Buy Rating, Announces Price Target of $35
Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), AbbVie (ABBV) and Immunome (IMNM)
Immunome (IMNM) Receives a Buy From Wedbush
Immunome Analyst Ratings
Wedbush Maintains Outperform on Immunome, Raises Price Target to $33
Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), United Therapeutics (UTHR) and Immunome (IMNM)
TD Cowen Reaffirms Their Buy Rating on Immunome (IMNM)
Leerink Partners Sticks to Their Buy Rating for Immunome (IMNM)
Immunome Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Immunome (IMNM) and Simulations Plus (SLP)
Immunome Analyst Ratings